Form 4: Dyne Therapeutics Director Jason Rhodes Granted 35,000 Stock Options

Dyne Therapeutics, Inc. Director Jason P. Rhodes was granted 35,000 stock options with an exercise price of $11.96, vesting on the earlier of May 30, 2026, or the 2026 Annual Meeting of Stockholders.

Summary

• Jason P. Rhodes, a Director of Dyne Therapeutics, Inc. (DYN), acquired 35,000 stock options on May 30, 2025.
• The options have an exercise price of $11.96 per share.
• The shares underlying the option are scheduled to vest in full on the earlier of May 30, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
• The options expire on May 29, 2035.
• Mr. Rhodes disclaims beneficial ownership of these securities for Section 16 purposes, except for his pecuniary interest, as he is obligated to transfer economic benefit to Atlas Venture Life Science Advisors, LLC.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of continued alignment between management/board and shareholder interests, and a standard practice for incentivizing long-term commitment. It does not, however, provide new information on operational performance or financial health.

Positives

• The grant of 35,000 stock options to Director Jason P. Rhodes aligns his interests with long-term shareholder value, as the options vest over time and are subject to continued service.
• The exercise price of $11.96 provides an incentive for the director to contribute to the company's stock price appreciation.

Future Outlook

The vesting schedule of the stock options, tied to continued service until at least May 30, 2026, indicates an expectation of ongoing commitment from Director Jason P. Rhodes to Dyne Therapeutics' long-term strategic goals.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries to attract and retain experienced directors and executives, aligning their incentives with the company's long-term success and drug development milestones.

Comparison to Industry Standards

• The grant of 35,000 stock options to a director is a standard form of equity compensation in the biotechnology sector, comparable to practices at similar-stage biopharmaceutical companies aiming to incentivize long-term commitment and performance. Specific comparable companies or projects are not detailed in this filing, as it focuses solely on the individual transaction.

Related Party Transactions

• The reporting person is obligated to transfer the economic benefit of the option exercise to Atlas Venture Life Science Advisors, LLC, indicating a pre-existing arrangement related to his role as a member of Atlas Venture Associates XI, LLC.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's interests with long-term shareholder value creation.
• Employees: No direct impact on employees mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders mentioned in this filing.

Key Dates

Recommendation

Keywords

Dyne Therapeutics, DYN, Stock Option Grant, SEC Form 4, Insider Transaction, Director Compensation, Equity Compensation, Biotechnology, Pharmaceuticals